Cape Investment Advisory’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-40
Closed -$1.16K 282
2025
Q4
$1.16K Sell
40
-50
-56% -$1.5K ﹤0.01% 1178
2025
Q3
$2.5K Hold
90
﹤0.01% 643
2025
Q2
$2.19K Hold
90
﹤0.01% 924
2025
Q1
$1.87K Hold
90
﹤0.01% 901
2024
Q4
$2.12K Hold
90
﹤0.01% 873
2024
Q3
$2.3K Hold
90
﹤0.01% 808
2024
Q2
$2.11K Hold
90
﹤0.01% 780
2024
Q1
$2.59K Sell
90
-50
-36% -$1.5K ﹤0.01% 737
2023
Q4
$4.59K Hold
140
﹤0.01% 792
2023
Q3
$3.9K Hold
140
﹤0.01% 706
2023
Q2
$4.77K Hold
140
﹤0.01% 663
2023
Q1
$4.21K Buy
+140
New +$4.34K ﹤0.01% 710

Other funds holding ARKG

Cape Investment Advisory's ARKG Position: Q1 2026 in Review

Cape Investment Advisory sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 40 shares — an estimated $1.16K sold.

Cape Investment Advisory first reported a position in ARKG in Q1 2023 and held it in 12 quarters. The position peaked at $4.77K in Q2 2023. 219 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Cape Investment Advisory reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
  • Cape Investment Advisory sold 40 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $1.16K.
  • Cape Investment Advisory first reported a position in ARK Genomic Revolution ETF in Q1 2023 and held it in 12 quarters.
  • Cape Investment Advisory's ARK Genomic Revolution ETF position peaked at $4.77K in Q2 2023.
  • 219 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Cape Investment Advisory's 13F filing for Q1 2026, filed 15 May 2026.